150 related articles for article (PubMed ID: 20811370)
1. Deal watch: Metabolex and Sanofi-Aventis partner on GPCR agonists for type 2 diabetes.
Nat Rev Drug Discov; 2010 Sep; 9(9):670. PubMed ID: 20811370
[No Abstract] [Full Text] [Related]
2. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
Kang SU
Drug Discov Today; 2013 Dec; 18(23-24):1309-15. PubMed ID: 24060477
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
4. Potential remains for PPAR-targeted drugs.
Jones D
Nat Rev Drug Discov; 2010 Sep; 9(9):668-9. PubMed ID: 20811368
[No Abstract] [Full Text] [Related]
5. Modulating GPR40: therapeutic promise and potential in diabetes.
Poitout V; Lin DC
Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
[TBL] [Abstract][Full Text] [Related]
6. The significance of GPR119 agonists as a future treatment for type 2 diabetes.
Dhayal S; Morgan NG
Drug News Perspect; 2010 Sep; 23(7):418-24. PubMed ID: 20862393
[TBL] [Abstract][Full Text] [Related]
7. Development of novel ligands for peptide GPCRs.
Moran BM; McKillop AM; O'Harte FP
Curr Opin Pharmacol; 2016 Dec; 31():57-62. PubMed ID: 27607913
[TBL] [Abstract][Full Text] [Related]
8. 32nd National Medicinal Chemistry Symposium--medicinal chemistry developments for neurodegeneration, diabetes and cancer.
Gater D
IDrugs; 2010 Aug; 13(8):514-6. PubMed ID: 20721817
[TBL] [Abstract][Full Text] [Related]
9. Molecule of the Month. TAK-875.
Drug News Perspect; 2010 Dec; 23(10):667. PubMed ID: 21180652
[No Abstract] [Full Text] [Related]
10. Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development.
Li Z; Qiu Q; Geng X; Yang J; Huang W; Qian H
Expert Opin Investig Drugs; 2016 Aug; 25(8):871-90. PubMed ID: 27171154
[TBL] [Abstract][Full Text] [Related]
11. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
12. GPR119 agonists 2009-2011.
Buzard DJ; Lehmann J; Han S; Jones RM
Pharm Pat Anal; 2012 Jul; 1(3):285-99. PubMed ID: 24236842
[TBL] [Abstract][Full Text] [Related]
13. Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes.
Zhou Y; Wang Y; Zhang L; Tang C; Feng B
Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800267. PubMed ID: 30740769
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and SAR of a novel series of heterocyclic phenylpropanoic acids as GPR120 agonists.
Zhang X; Cai C; Winters M; Wells M; Wall M; Lanter J; Sui Z; Ma J; Novack A; Nashashibi I; Wang Y; Yan W; Suckow A; Hua H; Bell A; Haug P; Clapper W; Jenkinson C; Gunnet J; Leonard J; Murray WV
Bioorg Med Chem Lett; 2017 Aug; 27(15):3272-3278. PubMed ID: 28642104
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of GPR120: a patent review.
Halder S; Kumar S; Sharma R
Expert Opin Ther Pat; 2013 Dec; 23(12):1581-90. PubMed ID: 24094095
[TBL] [Abstract][Full Text] [Related]
16. Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes.
Winters MP; Sui Z; Wall M; Wang Y; Gunnet J; Leonard J; Hua H; Yan W; Suckow A; Bell A; Clapper W; Jenkinson C; Haug P; Koudriakova T; Huebert N; Murray WV
Bioorg Med Chem Lett; 2018 Mar; 28(5):841-846. PubMed ID: 29456108
[TBL] [Abstract][Full Text] [Related]
17. Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
Du X; Kim YJ; Lai S; Chen X; Lizarzaburu M; Turcotte S; Fu Z; Liu Q; Zhang Y; Motani A; Oda K; Okuyama R; Nara F; Murakoshi M; Fu A; Reagan JD; Fan P; Xiong Y; Shen W; Li L; Houze J; Medina JC
Bioorg Med Chem Lett; 2012 Oct; 22(19):6218-23. PubMed ID: 22926069
[TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
Lizarzaburu M; Turcotte S; Du X; Duquette J; Fu A; Houze J; Li L; Liu J; Murakoshi M; Oda K; Okuyama R; Nara F; Reagan J; Yu M; Medina JC
Bioorg Med Chem Lett; 2012 Sep; 22(18):5942-7. PubMed ID: 22884988
[TBL] [Abstract][Full Text] [Related]
19. Deal watch: CureDM licenses regenerative diabetes therapy to Sanofi-Aventis.
Nat Rev Drug Discov; 2010 Jun; 9(6):422. PubMed ID: 20514059
[No Abstract] [Full Text] [Related]
20. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
Shah U
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
